Physician profile
Mark Schwartz
NPI 1467469148
$3,502.41
in general payments reported to CMS, 2019-2025
13 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $836 · 2021: $567 · 2022: $661 · 2023: $270 · 2024: $79.43 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $926.36 | 2019-2025 | Precision7, Dailies Total1, Precision 1 |
| Carl Zeiss Meditec, INC. | $793.97 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $393.69 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $235.26 | 2022-2024 | Xiidra, Miebo |
| Coopervision INC. | $234.26 | 2020-2025 | Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $230.58 | 2019 | |
| Abbvie INC. | $124.41 | 2025 | |
| Eyevance Pharmaceuticals LLC | $115.78 | 2021 | |
| Dompe US, INC. | $115.09 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $112.27 | 2021 | |
| Sun Pharmaceutical Industries INC. | $111.85 | 2023 | Cequa |
| Allergan, INC. | $93.84 | 2022 | |
| Rxsight INC | $15.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.